Why Is Intellia Therapeutics Stock Trading Lower On Friday?
1. Intellia prioritizes NTLA-2002 and nex-z therapies for 2025. 2. NTLA-2002 targets hereditary angioedema with Phase 3 study results. 3. Nex-z shows promise in halting ATTR amyloidosis progression. 4. Company reducing workforce by 27%, projecting $8 million restructuring cost. 5. Intellia has $862 million cash, supporting operations until mid-2027.